Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia
- PMID: 11012743
- DOI: 10.1046/j.1365-2559.2000.00993.x
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia
Abstract
Aims: Bone marrow histopathology reveals a striking heterogeneity at diagnosis of Philadelphia chromosome positive (Ph1+) chronic myelogenous leukaemia (CML). Based on semiquantitative evaluations of the number of megakaryocytes and the content of fibres, various histological subtypes have been postulated. However, little information exists on whether these groups represent stable categories of the different classification systems and whether therapeutic regimes exert any influence on the putative shift of histological patterns.
Methods and results: A retrospective clinicopathological study was performed on 396 bone marrow biopsies derived from 173 patients. There were at least two representative trephines taken at diagnosis and at median intervals of 16 months. Processing of the specimens involved immunostaining with CD61 (megakaryopoiesis) and Ret40f (erythropoiesis) and Gomori's silver impregnation technique. Based on morphometric analysis and in accordance with the general appearance of bone marrow histology three different histological subtypes were distinguished. These consisted of a granulocytic (51 patients), a predominantly megakaryocytic (73 patients) and a myelofibrotic pattern (49 patients). Follow-up biopsies revealed that a significant transition of histological groups occurred and that, independently of treatment modalities, the myelofibrotic category was associated with an unfavourable prognosis. Of the 124 patients without myelofibrosis at onset, 42% later transformed into the myelofibrotic subtype. However, these patients showed no prevalence of either a pre-existing granulocytic or megakaryocytic growth. Myelofibrotic changes were significantly associated with interferon (IFN) and busulfan (BU) therapy. On the other hand, a transition of a myelofibrotic into a nonfibrotic subtype was detectable in 17 of the 49 patients under study and related to hydroxyurea (HU) treatment.
Conclusions: Histological classification systems of bone marrow features in CML do not represent stable patterns, but may be significantly altered by therapy, in particular IFN and HU.
Similar articles
-
[Histologic and hematological findings in CML. A comparative immunohistochemical-morphometric and clinical study on bone marrow biopsies from 604 patients derived from two institutes of pathology (Cologne/Freiburg)].Pathologe. 2000 Jan;21(1):39-54. doi: 10.1007/s002920050005. Pathologe. 2000. PMID: 10663668 German.
-
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.Am J Clin Pathol. 2000 Jul;114(1):57-65. doi: 10.1309/XMGX-7HQ8-7PLU-LQ9M. Am J Clin Pathol. 2000. PMID: 10884800
-
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.Br J Haematol. 2000 Jan;108(1):64-71. doi: 10.1046/j.1365-2141.2000.01819.x. Br J Haematol. 2000. PMID: 10651725
-
Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia.Leuk Lymphoma. 2001 Sep-Oct;42(5):855-62. doi: 10.3109/10428190109097704. Leuk Lymphoma. 2001. PMID: 11697640 Review.
-
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.Histol Histopathol. 2004 Jan;19(1):239-50. doi: 10.14670/HH-19.239. Histol Histopathol. 2004. PMID: 14702192 Review.
Cited by
-
Hematologic aspects of myeloablative therapy and bone marrow transplantation.J Clin Lab Anal. 2005;19(2):47-79. doi: 10.1002/jcla.20055. J Clin Lab Anal. 2005. PMID: 15756708 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical